- Expands development pipeline with planned Phase 2 clinical trial for dry AMD Kuria Therapeutics, a pharmaceutical company developing a...

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...